Boots

Can you describe the effects of your most recent acquisition?
The acquisition of Clearasil in December 2000 will make Boots Healthcare International's leading edge acne and skincare technology more accessible to a broader customer base, ie. in new markets (such as the US and Japan, which together account for 50% of Clearasil sales) and new channels (including grocery distribution in Continental Europe). Appropriate partners or distributers will be appointed to maximise the potential from these new opportunities. The Clearasil acquisition also opens up the US and Japanese markets to Boots Healthcare International's full product portfolio. Boots Healthcare International has appointed an integration team from across its business to manage the transition of the Clearasil brand from P&G and it has already taken full control of the Clearasil business in the UK, Ireland, Australia, New Zealand and India.
Also in December 2000, Boots became the first major reta...